CION Ameerpet
Practical · Reviewed by CION Oncologists · NABH Accredited
Immunotherapy Cost — And What Unlocks It
This is the most expensive treatment discussed anywhere on this site, and there is no purpose in pretending otherwise — for many families cost genuinely determines whether it is an option. What is worth knowing before anything else is that access is determined by a comparatively inexpensive test. Eligibility depends on your tumour’s mismatch repair or microsatellite instability status, so a tumour that has never been tested cannot be considered for this treatment at all. Testing is the cheapest thing that unlocks the most expensive thing. This page covers that, what determines the total, and the routes to access that exist.
- Testing is the gateway — an untested tumour is not eligible
- Cost depends on duration — not a fixed number of cycles
- Routes to access exist — schemes, assistance programmes, trials
- Side effects can add cost — immune-related effects need treating
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What Determines the Total
Different from chemotherapy in one important respect: there is usually no fixed number of cycles.
| Factor | What it means |
|---|---|
| Whether you are eligible at all | Determined by mismatch repair or microsatellite instability status, and in some settings by use in combination with targeted therapy. The gateway question, and the cheapest to answer. See MMR and MSI testing. |
| Duration, not cycle count | Treatment is generally continued while it is working and tolerated rather than for a set number of cycles. That changes the financial planning question entirely — it is an ongoing commitment rather than a defined course. |
| Infusion interval | Given at regular intervals of some weeks. The interval and the dosing schedule affect how the cost accrues over a year. |
| Whether it is combined with other treatment | It may be given with chemotherapy, or with an anti-angiogenic targeted agent in mismatch repair proficient disease. Combinations cost more and should be costed together. See targeted therapy. |
| Day-care and monitoring | Facility time, nursing, and regular blood tests including thyroid, liver and kidney function to detect immune-related effects early. Recurring and easy to leave out of a mental total. |
| Managing side effects | Immune-related effects can affect the thyroid, bowel, liver, skin and lungs. Most are manageable; some require additional medication or admission. This is the item that most often exceeds an estimate. See immunotherapy. |
Ask what a year of treatment would cost, not what one infusion costs. Because treatment continues while it is working rather than for a fixed course, a per-infusion figure tells you very little about what you are committing to. A twelve-month projection including monitoring is the number to plan against.
Did You Know? There is a specific and avoidable failure that occurs repeatedly in advanced endometrial cancer: a woman is told her options are exhausted when her tumour was never molecularly tested. Mismatch repair testing is inexpensive relative to almost everything else in cancer care, it can nearly always be done retrospectively on tissue stored from the original biopsy or operation, and it determines eligibility for a class of treatment that has changed outcomes for women whose tumours are deficient. If you have advanced or recurrent disease and nobody has mentioned your mismatch repair status, that is the single most important question to ask — before any question about cost. Sources: NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma; ESMO Clinical Practice Guidelines on endometrial cancer.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Routes to Access
Five, and they are worth pursuing in parallel rather than one at a time.
- Insurance. Cover for immunotherapy varies considerably between policies and insurers. Establish what your policy covers, whether pre-authorisation is required, and whether there is a cap — before treatment starts rather than after. See insurance and cover.
- State health schemes. Coverage depends on the scheme, the empanelment status of the hospital and the specific approval in force. Ask your treating centre what applies to you rather than assuming either way.
- Patient assistance programmes. Manufacturers operate schemes that reduce cost for eligible patients, and they are frequently under-used because families do not know they exist. Ask your oncology team directly whether one applies to the treatment being proposed.
- Clinical trials. A legitimate route rather than a last resort. Trials may provide access to treatment that would otherwise be unaffordable, with close monitoring included. Ask what is open and whether you would be eligible.
- Treatment at a centre with these arrangements in place. Not every unit has established access to assistance programmes or trial portfolios. Where cost is the deciding factor, that is a legitimate reason to seek an opinion elsewhere. See second opinion.
Want Every Access Route Explored?
Testing completed if it was never done, and schemes, assistance programmes and trials checked.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get the Testing Done First
A comparatively cheap test determines access to the most expensive treatment. An untested tumour is not eligible.
Questions Worth Asking
Five that change what you know before committing.
"What is my mismatch repair status?"
Ask before anything else. If it has not been determined, ask for it to be done on the stored tissue — it can nearly always be performed retrospectively. This single result determines whether this class of treatment is available to you at all, and it is inexpensive relative to what it unlocks.
"What would a year of treatment cost, including monitoring?"
Not what one infusion costs. Because treatment continues while it is working rather than for a set number of cycles, a per-infusion figure does not tell you what you are committing to. Ask for a twelve-month projection including day-care charges and the regular blood tests.
"Is there a patient assistance programme?"
Ask your oncology team directly. Manufacturer schemes reducing cost for eligible patients exist and are widely under-used because families do not know to ask. It costs nothing to enquire and it occasionally changes what is possible.
"Would I be eligible for a trial?"
A legitimate question at any point rather than only when other options are exhausted. Trials may provide access to treatment that would otherwise be unaffordable, together with close monitoring. Ask what is open and what the eligibility criteria are.
"What happens if I have to stop?"
A difficult but practical question. Ask what the plan would be if treatment became unaffordable partway — what alternatives exist, and how the decision would be made. Knowing this in advance is better than facing it under pressure. See advanced disease treatment.
Told Your Options Are Exhausted?
Ask whether your tumour was ever molecularly tested. Bring your reports and we will check. The opinion is free.
Being Honest About This
Five things that are true and are worth saying plainly.
- For many families this treatment is not affordable, and that is a real constraint. Pretending otherwise helps nobody. What is worth pursuing is every access route in parallel rather than accepting the headline cost as final.
- Not being eligible is not a failure of care. Eligibility depends on tumour biology. A woman whose tumour is mismatch repair proficient is not being denied something — that treatment class is less likely to help her, and other options exist.
- Other systemic treatments remain. Chemotherapy, hormonal treatment and targeted classes all have roles, and hormonal treatment in particular is well tolerated and inexpensive for the right tumour. See hormone therapy.
- Symptom control is treatment, not a fallback. Managing pain, appetite and fatigue properly affects both how you feel and what you can tolerate, and it should run alongside whatever else is happening. See living with advanced disease.
- Say plainly if cost is the obstacle. Teams cannot pursue schemes, assistance programmes or trials they have not been asked about, and families frequently stay silent out of embarrassment. It is the most practical sentence you can say in that consultation.
Why Testing Comes Before Costing
It is inexpensive, it can be done on tissue you already gave, and it determines whether the conversation happens at all.
MMR / MSI testing as standard
Tumour board for every diagnosis
Slides reviewed, not just the summary line
Costs explained before you commit
Psycho-oncology and nutrition on the team
Second opinions welcomed, not resented
Take The Next Step
Ask About a Patient Assistance Programme
They exist, they are under-used, and it costs nothing to ask.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Immunotherapy Cost — Frequently Asked Questions
Why does testing matter before cost?
Because eligibility for this class of treatment is determined by your tumour's molecular characteristics, principally mismatch repair or microsatellite instability status. A tumour that has never been tested cannot be considered for it at all, whatever your ability to pay. The test is inexpensive relative to almost everything else in cancer care and can nearly always be performed retrospectively on tissue stored from your original biopsy or operation. If you have advanced or recurrent disease and nobody has mentioned your mismatch repair status, that is the most important question to ask — before any question about cost.
Why can nobody tell me the total cost?
Because unlike chemotherapy, which is given for a planned number of cycles, immunotherapy is generally continued for as long as it is working and being tolerated. There is usually no fixed endpoint at the outset, so the total depends on duration. That changes the financial planning question entirely: instead of asking what a course costs, ask what a year of treatment would cost including day-care charges and the regular blood tests needed to monitor for immune-related effects. A twelve-month projection is the number to plan against, and it should be provided in writing.
Is there any way to reduce the cost?
Several routes exist and they are worth pursuing in parallel rather than sequentially. Insurance cover for immunotherapy varies considerably between policies, so establish exactly what yours covers and whether pre-authorisation is needed before treatment starts. State health scheme coverage depends on the scheme and on the hospital's empanelment. Manufacturer patient assistance programmes reduce cost for eligible patients and are widely under-used simply because families do not know to ask. And clinical trials are a legitimate route that may provide access along with close monitoring — ask what is open and whether you are eligible.
What if I am not eligible for immunotherapy?
That is a matter of tumour biology rather than a failure of your care. Immune checkpoint inhibition works particularly well in mismatch repair deficient tumours because they carry a high mutational burden that makes them visible to the immune system; in proficient tumours it is less likely to help alone, though it may be used in combination with targeted therapy. Other systemic options remain: chemotherapy, targeted classes, and hormonal treatment, which is well tolerated and inexpensive and can be effective for low-grade hormone-receptor-positive disease. Ask your oncologist what your profile makes available.
What should I do if I simply cannot afford it?
Say so plainly to your treating team, early. Families frequently stay silent out of embarrassment, and teams cannot pursue schemes, assistance programmes or trials they have not been asked about. Ask specifically about each route. Ask what alternatives exist and how they compare. Ask what would happen if treatment had to stop partway, so that the decision is understood in advance rather than faced under pressure. And ensure that symptom control runs alongside whatever is decided, because managing pain, appetite and fatigue properly affects both how you feel and what you can tolerate.
Medical disclaimer: This page explains what determines the cost of immunotherapy for endometrial cancer and the routes to access. It is reviewed by a CION oncologist, does not name individual drugs, and deliberately does not publish price figures, because costs vary with the agent, duration, combination, centre and funding arrangement. Eligibility depends on tumour molecular characteristics and should be assessed by your treating team. Insurance and state scheme coverage should be confirmed directly with the insurer or scheme before treatment begins.